

CHANGE OF MANAGING DIRECTOR

PERTH, Australia and SAN FRANCISCO, California – 17 September 2025

PYC Therapeutics Limited (ASX:PYC) (PYC or the Company) announces the appointment of Chairman Mr Alan Tribe as the Company's Managing Director following the resignation of Dr Rohan Hockings as Chief Executive Officer and Executive Director. Dr Hockings has given 2 months' notice and it is currently expected that he will leave the Company by 16 November 2025.

Since joining the Board in 2018, Mr Tribe has brought his extensive corporate and commercial experience to the Company and has worked closely with executive management. He is well versed in the Company's operations. There will be no changes to his current terms of engagement or remuneration. He will now be based in the Company's Perth office on a full-time basis.

Following this change:

- PYC will commence the search for a permanent Managing Director
- Alan Tribe has met with the executive and leadership teams across the four clinical programmes to ensure that each drug development programme remains on track and is progressing in line with expectations, timelines and budgets. Management focus will be on maintaining the performance in this area.
- The Polycystic Kidney Disease programme remains a priority and updates will continue to be provided on progress towards the milestones previously advised

As Managing Director, Alan Tribe will also assume responsibility for the Company's Investor Relations and Business Development activities. He commented:

"I would like to thank Rohan for his significant contributions to the Company and wish him well in the future. There will now be a robust search to select a successor who can lead the future growth and development of the Company for its Shareholders"

Additional details

The Employment Agreement for Alan Tribe are summarised in Annexure A to this ASX Announcement, in accordance with ASX Listing Rule 3.16.4.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development ¹.

For more information, visit pyctx.com, or follow us on [LinkedIn](#).

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited

CONTACT US

Investor relations and media contact
investor@pyctx.com



¹ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.2022232>

ANNEXURE A

Summary of Material Terms of Mr. Tribe's Executive Employment

Commencement date	17 September 2025
Position	Chairman and Managing Director
Term	Ongoing until terminated by either party
Fixed Annual Remuneration	\$80,000 per annum (including statutory superannuation)
Notice Period	6 Months

For personal use only